Comparison of continuation of postmenopausal hormone replacement therapy: Transdermal versus oral estrogen

Menopause

Volumn 5, Issue 3, 1998, Pages 152-156

  Ettinger, Bruce ^a   Pressman, Alice ^a   Bradley, Cathy ^b  

^a DIVISION OF RESEARCH   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Estradiol; Estrogen replacement therapy; Menopause; Patient compliance

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE;

ADULT; AGE; ARTICLE; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; RISK; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; PATIENT COMPLIANCE; POSTMENOPAUSE;

EID: 0031713886     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fracture Research Group. Ann Intern Med 1995;122:9-16.
2. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;313:1044-9.
3. Ettinger B, Li D-K, Klein R. Continuation of postmenopausal hormone replacement therapy: comparison of cyclic versus continuous combined schedules. Menopause 1996;3:185-9.
4. Cano A. Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre. Maluritas 1994;20(2-3):91-9.
5. Ross D, Rees M, Godfree V, et al. Randomised crossover comparison of skin irritation with two transdermal oestradiol patches. BMJ 1997;315:288.
6. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in post-menopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
7. Field CS, Ory SJ, Wahner HW, Herrmann RR, Judd HL, Riggs BL. Preventive effects of transdermal 17 beta-estradiol on osteoporotic changes after surgical menopause: a two-year placebo-controlled trial. Am J Obstet Gynecol 1993;168(1, Pt 1):114-21.
8. Cox DR, Oakes D. Analysis of survival data. New York: Chapman and Hall, 1984.
9. Berman RS, Epstein RS, Lydick E. Risk factors associated with women's compliance with estrogen replacement therapy. J Womens Health 1997;6:219-26.
10. Howie H, Heimer G. A multicenter randomized parallel group study comparing a new estradiol matrix patch with a registered reservoir patch. Menopause 1995;2:43-8.
11. Berger RS, Della Coppa G, Dillard CO. Skin tolerability and adhesion characteristics of a new matrix patch and a marketed reservoir patch for estradiol delivery. Menopause 1997;4:46-51.
12. Ravnikar VA. Compliance with hormone therapy. Am J Obstet Gynecol 1987;156:1332-4.
13. Berman RS. Patient compliance of women taking estrogen replacement therapy. Drug Inf J 1997;31:71-83.